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Abstract
The interest in non-invasive brain stimulation techniques 
is increasing in recent years. Among these techniques, 
transcranial direct current stimulation (tDCS) has been 
the subject of great interest among researchers because 
of its easiness to use, low cost, benign profile of side 
effects and encouraging results of research in the 
field. This interest has generated several studies and 
randomized clinical trials, particularly in psychiatry. In 
this review, we provide a summary of the development 
of the technique and its mechanism of action as well as 
a review of the methodological aspects of randomized 
clinical trials in psychiatry, including studies in affective 
disorders, schizophrenia, obsessive compulsive disorder, 
child psychiatry and substance use disorder. Finally, 
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we provide an overview of tDCS use in cognitive 
enhancement as well as a discussion regarding its 
clinical use and regulatory and ethical issues. Although 
many promising results regarding tDCS efficacy were 
described, the total number of studies is still low, 
highlighting the need of further studies aiming to 
replicate these findings in larger samples as to provide a 
definite picture regarding tDCS efficacy in psychiatry.
Key words: Non-invasive brain stimulation; Transcranial 
direct current stimulation; Psychiatry disorders; Review
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Transcranial direct current stimulation (tDCS) 
has been the subject of great interest among researchers 
because of its easiness to use, low cost, benign profile 
of side effects and encouraging results of research in 
the field. In this review, we provide a summary of the 
development of the technique and its mechanism of 
action as well as a review of the methodological aspects 
of randomized clinical trials in psychiatry and we provide 
an overview of tDCS use in cognitive enhancement 
as well as a discussion regarding its clinical use and 
regulatory and ethical issues. 
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INTRODUCTION 
The interest in the brain stimulation using electricity 
exists since the Roman Empire, when the physician 
Scribonius Largus described the application of the electric 
shocks from “torpedo fish” to relieve headache[1,2]. In 
recent history, the first report of cortical stimulation 
occurred in 1802, when Giovanni Aldini described the 
electrical stimulation of exposed human cortex. He also 
reported the use of a voltaic pile to perform transcranial 
electrical stimulation to treat melancholia[2,3]. In fact, 
the invention of the voltaic battery encouraged the 
application of electrotherapy for medical purposes 
and during the 19th and 20th centuries physicians 
started to use galvanic batteries to perform electric 
brain stimulation for the treatment of different mental 
disorders with heterogeneous, dubious results. 
Notably, these first interventions were largely empirical 
and uncontrolled. Only in the 1950s and the 1960s 
systematic research was conducted in animals models, 
studying the effects of direct current (DC) on changing 
cortical excitability, and in clinical trials, performing DC 
stimulation for the treatment of depressive or manic 
symptoms[2]. The interest on “brain polarization” (as 
transcranial DC stimulation was described at that time) 
declined during the 2nd half of the last century, with the 
social stigma related to electroconvulsotherapy and 
the “golden age” of psychopharmacology. Only in the 
last 15 years, the findings that weak, DC stimulation 
delivered transcranially (tDCS) could induce prolonged 
neuroplastic changes in cortical excitability[4,5] with 
functional effects in healthy subjects[6], contributed to 
a resurgence of the interest in this technique not only 
as research tool but also as a potential approach for 
the treatment of several psychiatric disorders, such 
major depressive disorder, schizophrenia, obsessive-
compulsive disorder and also other psychiatric and 
neurological disorders[7-11].
Technical aspects and mechanisms of action of tDCS
tDCS is described as a non-invasive form of brain 
stimulation that uses a low-intensity, constant current 
applied directly to the head through scalp electrodes[12]. 
This form of brain stimulation can induce significant 
currents in superficial cortical areas (see The stimulated 
brain, Elsevier 2014, Chapter 2, for a review and further 
references) and, since the current used is sub threshold, 
it can modulate neuronal excitability without triggering 
action potentials[13], by facilitation or inhibition of 
spontaneous neural activity according to the polarity of 
the electrodes[14]. Generally, anodal stimulation induces 
an increase of cortical excitability, whereas cathodal 
stimulation decreases cortical excitability, effects that 
may last beyond the stimulation period[4,5], up to 30-120 
min[15]. In fact, the polarity-dependent effects are more 
complex and also dependent of the spatial organization 
of the cells: inward current flow at the cortex (anodal 
tDCS) generates hyperpolarization of apical dendritic 
regions of pyramidal cortical neurons and depolarization 
of somatic regions, whereas outward current flow 
(cathodal tDCS) results in somatic hyperpolarization 
and apical dendrite depolarization of pyramidal cortical 
neurons[16].
The effects of tDCS are not only determined by the 
polarity of the electrodes, but also with the dose[16]. 
This involves the current intensity (usually ranging 
between 0.5 to 2 mA)[12], the duration of stimulation 
(usually ranging between 5 to 40 min)[7] and the size of 
the electrodes that varies from 3 to 100 cm2[17]. These 
variables determine the current density (in A/m2) and 
the total charge (in Coulombs) applied. Notwithstanding, 
the actual current delivered to the cortex is also 
influenced by several other uncontrollable factors such 
as the impedance of the cephalic structures[7]. 
The electrode placement on the scalp is usually 
determined using the international Electroencephalogram 
(EEG) 10-20 System[17]. Commonly, the active electrode 
is placed on the scalp, whereas the reference electrode 
can be placed on either another cephalic location 
(bipolar or bicephalic montage) or an extracephalic 
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location (unipolar or monocephalic montage), usually 
the shoulder or upper arm. The electric current enters 
the brain through the anode, passes through the 
scalp and skull before reaching cortical and subcortical 
regions and finally leaves through the cathode (The 
stimulated brain, Elsevier 2014, Chapter 2). The 
current flow produced reaches deep structures and, 
when using extracephalic electrodes, the midbrain 
and spinal cord as well. Importantly, the conventional 
montages used in tDCS present low precision - i.e., 
the current flow produced is not restricted to the area 
under the electrodes but in fact spreads out to other 
cortical regions between and around the electrodes[18].
The long-term effects of tDCS appear to operate 
through bidirectional modifications of post-synaptic 
connections similar to long-term potentiation (LTP) and 
long-term depression (LTD), occurring through NMDA-
depended mechanisms[19]. Indeed, repeated tDCS 
sessions might further increase the duration of long-
term effects on behavioral outcomes[20]. 
Methodological aspects in clinical tDCS research 
Over the past years, tDCS has been increasingly used 
in clinical research, from basic neuroscience research 
to a tool in the treatment of various neurologic and 
psychiatric disorders[21,22]. In order to identify whether 
the effects of tDCS are non-specific or random, the 
use of a placebo (sham) group is mandatory in clinical 
trials. Indeed, the use of placebo is a standard method 
to blind participants and health care providers in 
randomized, controlled trials[23]. Within this context, the 
development of reliable methods of sham stimulation 
is challenging[24], as blinding failure can compromise 
evaluations, resulting in biased assessment of intervention 
effects. 
The sham stimulation, method validated by Gandiga 
and colleagues[25], is currently used in almost all tDCS 
clinical trials. The procedure involves short-lasting 
manual or automatic increase and decrease of current 
delivered during the first moments (30-60 s) of the 
stimulation session in order to simulate the same skin 
sensations of the verum stimulation[25-27]. Palm and 
colleagues[28] reported that using this blinding method 
the subjects were not able to distinguish between 
active and sham stimulation applied on prefrontal 
areas. However, in this study, the investigators were 
able to identify between active vs sham stimulation 
group based on the skin redness provoked by the 
active stimulation. In another research, Ambrus and 
colleagues suggested that this method of blinding 
is effective, not because the sham fade-out phase 
mimics the presumed disappearance of the sensations 
in the verum stimulation conditions, but because, 
the cutaneous sensations associated with the sham 
stimulation persist after the ramp-down phase[29].
Another concern of tDCS detection involves current 
dose, which seems to be associated with active tDCS 
detection[28] since it is related to immediate adverse 
effect, especially discomfort sensation. In a randomized 
double blind crossover trial with 100 healthy volunteers, 
O’Connell et al[30] suggest that blinding in studies using 
tDCS at intensities of 2 mA is inadequate once the 
participants correctly judged the stimulation condition.
Furthermore, some authors suggest that longer 
ramp-in phases are preferable for blinding purposes, 
especially when daily tDCS sessions are applied[24,31]. 
In fact, randomized clinical trials (RCTs) tDCS trials, 
which use parallel designs, might provide a more 
adequate blinding. In a recent RCT for major depression 
with a factorial design and two active interventions 
(sertraline/placebo and 2 mA active/sham tDCS), 
blinding assessment of the pharmacological and non-
pharmacological interventions was comparable, with 
correctly blinding guessing primarily associated with 
clinical improvement and adverse effects and not 
blinding failure[24].
Skin redness and discomfort are common adverse 
effects that can harm tDCS blinding, and some studies 
have been performed in order to control them. Gua-
rienti et al[32] found that topical pre-treatment with 
ketoprofen 2% significantly attenuated the tDCS-
induced erythema, with a medium effect as compared 
to placebo. Moreover, the unblinding of this adverse 
effect can be managed by avoiding the awareness 
of participants (for instance, looking at the mirror or 
contacting peers following stimulation) and raters (for 
instance, by adopting a rest period between tDCS 
session and the clinical interview). McFadden et al[33] 
reported the reduction of pain and discomfort associated 
with tDCS by using local anesthetics. A recent report 
showed that pretreatment with benzocaine 6%, a 
topical numbing agent, can decrease the discomfort in 
subjects during the stimulation using high definition (HD) 
electrode design, which can enhance the efficiency of 
the sham controlled studies[34].
Adverse effects and safety 
The general impression is that tDCS is a safe technique 
with mild and transient adverse effects (AEs). Human 
data on safety and tolerability are largely provided 
from single-session studies in healthy volunteers. In a 
meta-analysis, Brunoni and colleagues[31] showed that 
tDCS presents a benign profile of side effects when 
used in 1-2 sessions for healthy volunteers; however, 
they referred that only 56% of all reviewed studies 
reported the presence/absence of AEs, concluding 
that AEs are being insufficiently reported during tDCS 
clinical research. 
According to this meta-analysis, the most common 
adverse effects are detected in the active group, 
among which itching, tingling, headache, burning 
sensation and discomfort (Table 1).
Although well investigated in adults, there is no 
specific guidance for tDCS dosage in children. The 
few studies investigating tDCS among the pediatric 
population indicated that adverse effects were similar 
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enhance them[41].
Compared to repetitive transcranial magnetic 
stimulation (rTMS), tDCS is a relatively cheaper, easier 
to use, more portable technique with even less adverse 
effects. Such appealing characteristics motivated 
the research of using tDCS for the treatment of 
neuropsychiatric disorders (for a review see[11]), and, 
among them, tDCS has been showing particularly posi-
tive results in major depression.
Major depressive disorder
Major depressive disorder is a severe psychiatric disorder, 
chronic and prevalent, showing a life prevalence between 
6% and 12% and yearly between 3% and 11% in the 
whole world[42]. Besides that, proximately 80% of the 
patients present a recrudescence of depressive symptoms 
after one year of treatment with antidepressant drugs 
and up to 33% do not achieve complete remission after 
the use of 2 or 3 medication trials, which characterizes 
the treatment resistant depression[43]. In view of its 
complexity and heterogeneity, with variations in it 
is etiology, symptoms, course and response to the 
treatment, further investigation aiming to refine the 
knowledge underlying neurobiology is needed, with 
the goal to identify circuits and brain areas connected 
with this pathology.
An important body of evidence coming from 
neuroimaging studies suggests that depression is a 
result of impairment in activity of neural circuits that 
connects the dorsolateral prefrontal cortex (DLPFC) and 
the limbic system to other subcortical structures[44]. The 
current neural models of depression propose that the 
emotional deregulation is due to abnormalities in the 
dorsal neural system (cognitive control system) and the 
ventral neural system (emotional evaluation system)[45]. 
The dorsal system, which comprehends the DLPFC, 
dorsomedial PFC, the anterior dorsal cingulate gyrus 
and the hippocampus, is involved both in the cognitive 
processing of emotional input as much as the voluntary 
regulation of emotion. The ventral system, which 
comprehends the amygdala, insula, the ventral striate, 
dorsal cingulate gyrus and ventral PFC is critic for the 
identification of the emotional meaning from both 
internal or external stimuli, for the automatic generation 
and regulation (regulation without any conscious effort) 
of affective states, mediation of automatic response, 
dependent of the stimuli and context that results in 
the production of the affective states. It was proposed 
that increase of ventral neural system activity and 
decrease of the dorsal neural system activity can result 
mainly in attention impairment, in the identification of 
negative emotions and in other cognitive and vegetative 
symptoms of the depressive disorder[46].
tDCS in the major depressive disorder
In depression, the rationale of the montage with the 
anode positioned over the left DLPFC and the cathode 
over the right DLPFC, the right supraorbital area or in 
to adults, restricted to itching or tingling sensations 
at the stimulation site and without the reporting of 
any serious side effects[35]. A naturalistic study in 
14 children with language disorders showed that 10 
sessions of tDCS were well tolerated and the main side 
effect detected was irritability, followed by acute mood 
changes, tingling and itching[36].
However, due to anatomical and neurophysiological 
differences in the developing brain (i.e., skull thickness, 
cerebrospinal fluid volume, white and gray matter 
volumes) the dose parameters considered safe and 
efficacious for the use in adults should be adjusted to 
achieve comparable results in children[37]. 
Recently, Kessler et al[37] conducted a study in order 
to evaluate the safety aspects of tDCS in children. 
Using magnetic resonance imaging (MRI), they derived 
head individual models by two neurologically normal 
children and by three adults with different head sizes 
and circumferences; their analyses showed an overlap 
of sensitivity between adults with smaller head size 
and children aged between 8 and 12 years. Moreover, 
they highlighted to pay of caution in applying current 
intensities of 2 mA or greater in pediatric populations, 
due to the fact that the average of the dose of current 
over the cortical surface after the tDCS stimulation 
after might be higher in children than adults.
USE OF TDCS IN PSYCHIATRIC 
DISORDERS 
As a neuromodulatory tool, tDCS was reappraised in 
the turn of the 21st century, with the seminal works 
of Priori[38], followed by Nitsche et al[4]. They showed 
that the induction of a weak, direct current through 
electrodes placed over the scalp could increase (anode) 
and decrease (cathode) cortical excitability beyond 
the period of stimulation. It is exact mechanisms 
of action are still being elucidated but it probably 
operates by inducing small changes (< 1 mV) in the 
membrane potential[39], thus acting in the frequency of 
spike timing and modifying net cortical excitability[40]. 
The mechanisms of action of tDCS occur also at the 
synaptic level. For instance, glutamate antagonists 
abolish tDCS after-effects, while NMDA-agonists 
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Table 1  Adverse effects associated with transcranial direct 
current stimulation
Adverse effects Active1 Sham1
Itching 46 (39.3%) 27 (32.9%)
Tingling 26 (22.2%) 15 (18.3%)
Headache 17 (14.8%) 13 (16.2%)
Burning 10 (8.7%) 8 (10%)
Discomfort 12 (10.4%) 11 (13.4%)
1Number of subjects reporting adverse symptom (% in the sample). 
Adapted from Brunoni et al[31], 2011. A systematic review on reporting and 
assessment of adverse effects associated with transcranial direct current 
stimulation.
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an extra-cephalic position[7] rests on: (1) the prefrontal 
asymmetry theory of depression, with relative 
hypoactivity over the left and relative hyperactivity 
over the right[47,48]; (2) the improvement in working 
memory and affective processing observed after one-
single tDCS session in depressed patients[49-51]; (3) the 
top-down, neuromodulatory effects of tDCS, possibly 
reversing the imbalance between hypoactive cortical 
areas and hyperactive subcortical areas[48]; and (4) 
the clinical effects observed in rTMS using either rapid, 
facilitatory stimulation over the left DLPFC and slow, 
inhibitory stimulation over the right DLPFC[52,53].
In the beginning of this century, some RCTs investi-
gating the efficacy of tDCS for treating depression 
have showed promising results. Fregni et al[54] (n = 10, 
tDCS given at 1 mA, 20 min per session, 5 sessions on 
alternate days) and Boggio et al[55] (n = 40, 2 mA, 20 
min, 10 sessions on consecutive weekdays) both found 
tDCS more effective than a sham control. Negative 
results were found in the study conducted by Loo et 
al[56] (n = 40, 1 mA, 20 min, 5 sessions on alternate 
days followed by 5 further active treatments) clinically 
meaningful improvement was seen with active tDCS 
over 10 sessions of treatment, but differences failed to 
reach statistical significance over the initial 5-session 
sham-controlled comparison period.
Although a variety of studies have found promising 
results in the reduction of depressive symptoms treated 
with tDCS protocols, two recent meta-analyses found 
different results. While Kalu et al[57] conducted a meta-
analysis that found improvement in the depressive 
symptoms in the active group compared with the sham 
tDCS group, Berlim et al[58] did not find significant 
differences in the rates of response between the active 
and the sham treated groups, although it is important to 
emphasize that those meta-analyses considered distinct 
outcomes. Kalu et al[57] considered the size of the effect 
based on the depression classification scores while Berlim 
et al[58] focused on the rates of remission and response. 
Some reasons for these mixed findings include relatively 
small sample sizes, disparate treatment modalities 
(including number of sessions, cathode positioning, 
duration and intensity of the sessions, etc.) and different 
depression characteristics (regarding refractoriness, 
severity, mean age, unipolar vs bipolar depression and 
concomitant use of pharmacotherapy) in the sample. In 
fact, a more recent meta-analysis[8] found that active vs 
sham tDCS had greater efficacy considering depression 
improvement as well as response and remission rates. 
The largest controlled study so far about the 
application of tDCS in depression was recently published 
by Brunoni et al[59]. The authors made a controlled 
trial with 120 patients with depression. The results of 
this factorial study in which patients were randomly 
assigned to receive active tDCS/sham tDCS and verum 
sertraline/placebo showed a significant improvement on 
the depressive symptoms for the ones that took only 
active tDCS or in combination with sertraline.
Nonetheless, further randomized clinical trials 
are necessary and, in fact, several trials evaluating 
the clinical efficacy of tDCS in depression are being 
currently performed worldwide. Therefore, in the next 
years a definite answer regarding the role of tDCS in 
the therapeutic arsenal of depression is expected.
Bipolar disorder
The etiopathogenic and physiopathological mechanisms 
of bipolar depression are not yet completely known. 
One important factor, however, seems to be the 
“hereditary-genetic”. While the general risk to 
develop the bipolar disorder in the general population 
is between 1% and 2%, it goes up to 9% in first 
degree relatives of a Bipolar “carrier”. The conformity 
between homozygous twins varies between 40% and 
50% and the heritability (proportion of disease risk 
in the population due to genetic variation) can reach 
80%-85%[60].
From the neuroimaging point of view, several studies 
indicate the commitment of some structures involved 
in the affective regulation, such as PFC, anterior 
cingulate gyrus and amygdala. Neurophysiologic 
studies in bipolar patients, in turn, indicate executive 
and attention deficits, corroborating the idea of a 
commitment of the PFC[61].
TDCS in bipolar depression
A recent study enrolling 31 patients (14 with bipolar 
depression and 17 with unipolar depression) had all the 
subjects submitted to a specific protocol: 5 sessions of 
tDCS with 20 min each, using anodic stimulation over 
the left DLPFC. The treatment was well tolerated by 
all and no significant adverse effects were observed. 
After the fifth tDCS session, depressive symptoms 
decreased in both groups and the beneficial effects 
lasted for a month[62].
Loo et al[63], in which eight patients with bipolar depr-
ession (four in each group) were recruited, did not show 
important results in RCT phase, however on follow up 
approach the outcomes were more expressive. Thus, 
new studies are needed to reinforce the rationale of use 
in order to validate this technique in this illness.
Schizophrenia 
Schizophrenia is a mental disorder that occurs in 
0.5%-1.5% of the population[64]. The clinical sympto-
matology of the disorder can be divided in three groups 
of symptoms: positive, negative and cognitive. The 
positive symptoms are characterized by hallucinations, 
delusions, thought disorders and movement disorders. 
Negative symptoms involve blunted affect, lethargy, 
and social withdrawal. Traditional antipsychotic 
medications have limited efficacy in treating these 
chronic, often refractory, symptoms[65]. It is appraised 
that patients treated with antipsychotics remit in 30% 
of cases, respond partially in 30% and do not respond 
in about 40%[66]. The best pharmacological option is 
clozapine, which is the first-line drug for patients with 
treatment-resistant schizophrenia, defined as the failure 
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of two adequate antipsychotic trials[67]. About 30% 
of patients treated with clozapine responds partially 
and these cases are described as super-refractory[67]. 
These patients are treated of different ways. Even if 
the evidence regarding non- pharmacological therapies 
is still limited, a recent meta-analyses have shown 
promising results in the application of rTMS in the 
treatment of auditory verbal hallucinations and negative 
symptoms[68,69]. Neuroimaging studies have highlighted 
that these symptoms might be linked to abnormal brain 
activities within large dysfunctional brain networks. 
Auditory verbal hallucinations have been linked to 
fronto-temporal abnormalities with an hyperactivity 
in the left temporo-parietal junction[70] and negative 
symptoms have been linked to hypoactivity in the right 
and left prefrontal cortex[71].
Thanks to the excitatory effect of the anode and 
the inhibitory effect of the cathode described in the 
neurophysiological studies investigating the effect 
of tDCS on motor cortex excitability, it has been 
hypothesized that anodal tDCS applied over the left 
prefrontal cortex (hypoactive) combined with cathodal 
tDCS applied over the left temporo-parietal junction 
(hyperactive) could alleviate auditory hallucinations 
in patients with schizophrenia (for a review see 
Mondino[72]). In the same way, bifrontal tDCS with 
the anode placed over the left prefrontal region and 
the cathode over its right homologue or the right 
supraorbital region is assumed to decrease negative 
symptoms. Based on these hypotheses, several 
studies have investigated the clinical effects of tDCS 
in these two indications in schizophrenia. Current 
was set at an intensity of 2 mA and delivered during 
20 min. The electrodes were placed over the scalp of 
the subjects according to the 10/20 EEG international 
system. The center of the electrode was placed on a 
point situated midway between T3 and P3 to stimulate 
the left temporo-parietal junction and on F3 (F4) or 
between F3 and FP1 (F4 and FP2) to stimulate the left 
(right) prefrontal region.
Another study evaluated 20 patients with predominant 
negative symptoms and stable medication (> 3 wk) and 
they were randomized to active or sham stimulation 
groups[73]. Anode was placed over the left DLPFC and 
cathode over the right supraorbital area; tDCS was 
delivered once a day for 10 d. The active group showed 
significant amelioration in The Positive and Negative 
Syndrome Scale two weeks after the end of stimulation. 
Regarding bifrontal tDCS, only some case-studies 
have highlighted the potential interest of tDCS to 
reduce resistant negative symptoms[74,75] and catatonic 
symptoms[76].
Regarding safety, on the total amount reported 
in world literature of about 50 schizophrenic patients 
that have received tDCS, the technique appears to be 
remarkable safe in the short and medium-terms[77]. 
Regarding adverse effects, some reviews described 
only mild adverse effects associated to tDCS such as 
tingling, itching and fatigue, similarly as observed in 
literature[78,79].
Of note, two recent case studies have reported the 
clinical interest of original stimulation parameters using 
transcranial random noise stimulation. This kind of 
stimulation can be of interest to enhance clinical efficacy 
of transcranial stimulation[80,81]. Finally, in the literature 
there are only few studies that have investigated the 
clinical efficacy of tDCS in schizophrenia. Promising 
results have been reported but replication studies with 
larger samples are needed before any conclusion.
Obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) has a 2% 
lifetime prevalence in the general population[82,83]. 
Commonly, OCD symptoms begin during childhood and 
have a chronic course, causing severe impairments in 
both interpersonal and occupational functioning[84-86]. 
In addition, pharmacotherapy is only effective in 
40%-60% of patients[87], and cognitive-behavior 
therapy (CBT),which has been reported as the most 
effective treatment for OCD[88], is not readily available to 
the majority of patients. Overall, 30% of OCD patients 
are refractory to any first or second line treatments[89]. 
Thus, the search for a clearer understanding of disease 
etiology and the need for new approaches to treatment-
resistant patients are paramount.
It has been proposed that OCD results from mal-
functioning of cortico-striato-thalamo-cortical circuitry 
including the medial prefrontal cortex (i.e., supple-
mentary motor area-SMA and anterior cingulate cortex-
ACC), the dorsolateral prefrontal cortex, orbitofrontal 
cortex (OFC), and basal ganglia[90]. This model informed 
neurosurgical approaches to OCD, and resulted in 
effective invasive treatments as evidenced by the FDA 
humanitarian use approval for high frequency deep 
brain stimulation (DBS) in treatment-resistant cases[91]. 
However, the need for noninvasive alternatives for 
patients who do not respond to standard treatments 
(e.g., serotonin reuptake inhibitors or CBT) remains. 
While rTMS has shown promise when applied to the 
SMA and to the OFC[92], tDCS has been less investigated 
for the treatment of OCD. Therefore, questions about 
which areas should be targeted and which parameters 
should be used still need to be addressed. In one case 
report, tDCS resulted ineffective when applied to the 
DLPFC[10], whereas a 30% reduction in the Yale-Brown 
Obsessive Compulsive Severity Scale was found in a 
case of treatment-resistant OCD after cathodal tDCS to 
the pre-SMA[93]. Furthermore, D’Urso et al[94] reported, 
in a randomized cross-over trial of anodal vs cathodal 
tDCS to the pre-SMA, that the cathodal application 
was significantly superior to anodal tDCS in reducing 
OCD symptoms. The results of this study are in line 
with findings of clinical efficacy of inhibitory rTMS to 
pre-SMA[95], demonstrated to be hyperactive in OCD 
patients during performance of cognitive tasks related 
to attentional aspects of action control[96,97]. 
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The evidence deriving from the clinical efficacy of 
inhibitory rTMS and tDCS and from neurophysiological 
measures of altered motor cortex excitability in 
OCD[91], that normalized after 1-Hz rTMS to the pre-
SMA[98], suggests that the pre-motor/motor system 
is abnormally hyperactive in OCD, and that there is a 
pathophysiological link between such hyperexcitability 
and OCD symptoms. 
In this context, to optimize the effect of cathodal 
tDCS in OCD, simulated predictions of electric flow 
models would be an extremely useful strategy for 
the design of future tDCS trials. By applying this 
model, Senco et al[99] found that the application of 
the active electrode (cathode) over the pre-SMA, 
with the reference electrode (anode) positioned on an 
extracephalic location (i.e., the subject’s right deltoid), 
resulted in a distribution of the electrical field from 
the medial prefrontal cortex to the striatum, therefore 
reaching the cortical and subcortical brain areas which 
are crucially involved in the pathophysiology of OCD. 
Based on this model and on the promising results 
about the efficacy of cathodal tDCS to pre-SMA in 
treatment-resistant OCD, a randomized controlled trial 
testing the clinical and neurobiological effects of tDCS 
in OCD is underway.
TDCS in child psychiatry 
The first onset of a variety of mental disorders 
diagnosed in adults occurs in childhood or adolescence, 
as for instance, impulse-control disorders, attention 
deficit hyperactivity disorder (ADHD), phobias, separation 
anxiety disorder and substance use disorder[100]. Earlier 
onset is associated with treatment delay, longer 
duration of illness and poorer clinical and functional 
outcomes, being an important cause of burden during 
this period of life[101,102]. In this sense, the use of novel 
treatments such as tDCS, should also be considered 
for children and adolescents, and might constitute 
a promising therapeutic and diagnostic tool, as the 
capacity for brain plasticity is greater during this period 
of life[103]. tDCS would be also an interesting tool to 
explore which brain areas are particularly important 
in each stage of development both in healthy and 
pathological conditions[7]. Nevertheless, the scope of 
literature in child and adolescent psychiatry is still very 
limited, with the majority of studies being case reports 
and open label studies. 
An open study evaluating autistic patients with 
minimal verbal language have applied anodal tDCS 
over the Broca’s area to improve language acquisition 
and the results showed that mean vocabulary scores 
were significantly higher after the intervention Schneider 
et al[104]. One double-blind, sham-controlled trial 
with 12 youths (age range from 10 to 17 years) with 
schizophrenia evaluated the tolerability of tDCS. The 
patients were assigned to anodal or cathodal stimulation 
and both groups were stimulated for 20 min per day 
during 10 d. Although no clinical improvement was 
observed, this protocol was well tolerated, without 
reports of serious side effects Mattai[105]. No study has 
assessed so far the effect of tDCS for the treatment of 
major depression in children and adolescents. 
Attention deficit hyperactivity disorder is a behavioral 
diagnosis of early childhood where children often have 
changes in motor control development, and studies 
with adults suggested that anodal tDCS in the DLPFC 
may be associated with enhancement of cognitive 
performance[106]. Currently, there are an increasing 
number of studies investigating TMS as an evaluation 
and therapeutic tool in ADHD, but no studies regarding 
tDCS in children and adolescents with this diagnose.
During childhood and adolescence the developing 
brain is probably more sensitive to interventions. This 
might lead to better results comparing to adults, but 
also to an increased risk of side effects, related to 
possible negative or maladaptive plasticity[35]. For this 
reason, the application of tDCS in developmental age 
should be considered only after convincing evidence 
has been collected on adult populations, even when 
dealing with disorders usually first diagnosed in infancy, 
childhood, or adolescence. In the case of Autism, 
despite two reports of positive findings about the use 
of cathodal tDCS over the DLPFC for the treatment 
of some autism-related core behavioral symptoms D’
Urso[107] no study has involved so far autistic patients 
in the developmental age. Nonetheless, neuroplasticity 
in important brain areas can hardly be controlled in 
RCT even when using widely accepted and traditional 
treatments as psychotropic medication, so that the 
only available way to gather adequate data on efficacy 
and side effects is testing directly the specific target 
population[2]. Indeed, a recently published review of 
literature regarding non invasive brain stimulation in 
childhood and adolescence highlighted the importance 
of systematic research in dose-finding, with sham-
controlled, double-blinded studies that are capable to 
provide important information not available from open 
label studies[35]. 
Substance use disorders
The treatment of substance use disorders is usually 
difficult and challenging. The central reward pathway, 
critical in the mechanism of dependences, comprises 
the dopaminergic system including the mesolimbic 
cortical ventral tegmental area and projections to the 
nucleus accumbens and the prefrontal cortex[108,109]. 
Neuroimaging studies showed the important function 
of the prefrontal cortex in substance use disorders, 
being an important cortical structure in working memory 
and executive functions, two cognitive domains that 
are usually damaged in chemical dependencies[110]. 
In literature, only few studies have investigated the 
application of tDCS for the treatment of chemical 
dependencies. Nonetheless, these studies have shown 
a possible role of this technique for the treatment of 
these conditions, especially by stimulating the activity 
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of the prefrontal cortex. Thus, the efficacy of tDCS 
in treating substance use disorders deserves further 
investigation, as shown below.
Cocaine: Goriniet et al[111] used tDCS over the DLPFC 
in two samples of subjects (18 cocaine dependent 
users and 18 control subjects) to investigate the 
effects of increasing cortical excitability after right or 
left anodal stimulation. The subjects were randomized 
to receive left-anodal/right-cathodal stimulation, right-
anodal/left-cathodal stimulation, or sham (placebo) 
stimulation; each session was delivered at least 48 h 
apart. The results showed that the activation of the 
DLPFC (left and right) results in the reduction of risky 
behaviors in both, patients and control subjects, in 
cocaine dependent users. The authors concluded that 
in the future tDCS could represent a valuable tool for 
intervention in users of cocaine.
Alcohol: A randomized sham-controlled study in which 
13 subjects received three different types of bilateral 
stimulation of DLPFC with tDCS: (1) active anodal left 
and cathodal right tDCS; (2) active anodal right and 
cathodal left tDCS; and (3) sham tDCS, have shown a 
reduction of craving for alcohol in both active groups 
compared to the sham group[112]. 
Moreover, Klausset et al[113] studied 35 subjects 
randomized to receive active bilateral (left cathodal/
right anodal over the DLPFC) repetitive (five consecutive 
days) tDCS (2 mA, 35 cm2, two times daily stimulation 
for 13 min with a 20-min interval) or sham-tDCS. 
They observed that bilateral tDCS over DLPFC reduced 
relapse probability in severe alcoholic subjects and 
improved perception of quality of life.
Nicotine: Fregni et al[114] have investigated 24 patients, 
who received three different condition of a single tDCS 
session in a randomized order: sham stimulation, 
anode on the right DLPFC and anode the left DLPFC. 
The authors observed a reduction of craving in both 
active groups compared to the sham group. 
Another study evaluated the effects of five consecutive 
sessions of tDCS on DLPFC. Twenty seven patients 
were randomized into two distinct groups: left anode 
and sham stimulation. The results showed a small 
but significant reduction in cigarette consumption and 
craving in active vs sham groups[115].
A more recent study showed that anodal stimulation 
over the left DLPFC improved smoking-related negative 
affect, but did not improve the fissure. The authors 
studied 24 smokers who received one real session and 
one sham session of tDCS after overnight abstinence 
from smoking in two different days. They applied anodal 
tDCS to the left dorsolateral prefrontal cortex and 
cathode to the right supra-orbital area for 20 min with a 
current intensity of 2.0 mA[116]. 
Fecteau et al[117] rated two five-day tDCS regimens 
(active or sham). Stimulation was delivered over 
the right DLPFC at a 2 mA during 30 min in twelve 
adults. The main finding was a significant reduction in 
the number of cigarettes smoked when participants 
received active as compared to sham stimulation. 
Food: Fregni et al[118] conducted a study on healthy 
subjects who reported frequent food cravings. They 
designed a sham controlled crossover study, applying 
one session of tDCS stimulation (2 mA, 20 min) in 
three different conditions: anodal-left/cathodal-right 
DLPFC, cathodal-right/anodal-left DLPFC and placebo. 
They observed a reduction of cue-induced food 
craving when comparing active anodal left/cathodal 
right DLPFC over the other groups and a lower caloric 
ingestion when comparing active (both configurations) 
to sham group. 
Goldman et al[119] applied 1 session of tDCS (2 mA, 
20 min, anodal prefrontal dorsolateral cortex right) 
in healthy subjects that reporting food craving. The 
study showed a reduction of craving in both sham and 
active tDCS conditions. Moreover, the results indicated 
decreased ratings for specific food items when 
comparing active to sham tDCS. 
Cannabis: Boggio et al[120] studied the effect of tDCS 
on cannabis dependence. Twenty-five patients were 
divided into three distinct groups: anode left/cathode 
right, anode right/cathode left and sham stimulation. 
The results showed a significantly decrease of the 
craving for marijuana in the anodal right stimulation 
group.
USE OF TDCS IN COGNITION 
Results from several studies regarding the effects of 
tDCS stimulation suggest that it could induce clinical 
gains in major depressive disorder, schizophrenia 
and substance use disorders[121]. In many studies, 
researchers have noticed improvement in cognitive 
aspects of patients, such as working memory, 
attention, executive functions and processing speed[122]. 
Furthermore, reports have demonstrated its utility in 
the facilitation of several cognitive domains, such as 
implicit motor learning and visuo-motor learning[123,124], 
indicating its potential effectiveness on the modulation 
of behavior through the modulation of neurotransmitter-
dependent plasticity on the network level.
The results of some studies in patients with major 
depression suggest improvement in performance Digits 
Test[125], increasing of correct responses in affective Go-
no-go[51], improving of attention and working memory[49,63,126], 
cognitive control[127] and processing speed[126]. Some studies 
in patients with Alzheimer’s disease showed improvement 
in recognition memory[127] and visual recognition memory 
Boggio et al[128,129] after stimulation with tDCS. One 
study reported an improvement in learning probabilistic 
membership functions in schizophrenic patients after 
tDCS[130]. Another study in 18 schizophrenic patients 
showed an improvement in working memory[131]. Finally, 
a study of alcoholic subjects showed that after five 
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weeks of stimulation, the subjects showed significant 
improvement in executive functions[132].
With the same logic that the effects of tDCS showed 
cognitive improvement in psychiatric and neurological 
patients, studies with healthy subjects have shown that 
tDCS can promote changes in cognitive function after 
only one session or even after a series of sessions[6]. 
Several studies have demonstrated the effects of tDCS 
on different cognitive functions in healthy subjects[133]. 
In order to study further the relationship between 
tDCS and cognition, some researchers have decided 
to study neural underpinning effects on cognition. 
Supported by the observation that anodal tDCS over 
the left DLPFC could improve naming performance 
in healthy participants[134] investigated the putative 
neurophysiological mechanisms underpinning language 
production. The authors found the reduction of 
semantic interference after anodal stimulation. Other 
studies have been conducted to explore the inhibitory 
effect of the technique[133]. 
This area of study may contribute in the future in the 
investigation of the application of tDCS as an important 
non-invasive tool for the rehabilitation of cognitive 
functions. However, the studies so far available suggest 
that the changes in cognitive performance observed 
after tDCS stimulation are short-lived; this warrants 
more studies to better explore the development of 
the application of tDCS in patients with neurocognitive 
disorders.
REGULATORY ISSUES 
There are over 1200 tDCS publications in Pubmed, 
with more than 200 being clinical trials for multiple 
clinical disorders. The potential of tDCS for clinical 
practice has been demonstrated for psychiatric and 
cognitive disorders, as described above, for psychiatric 
conditions associated with neurologic disorders, such 
as depression in Parkinson diseases and stroke, but 
also for tinnitus, chronic pain and motor deficit due to 
different neurological diseases.
An interesting aspect of tDCS is that it has a low 
risk; it is simple to operate, being portable and having 
a relatively low cost. On the other hand these same 
characteristics increases the chance of misuse, such as 
enhancement application, recreational using and using 
without supervision (as discussed below in ethical 
issues), which increases the need for regulations 
concerning the use of tDCS.
A worldwide implementation of tDCS regulation is 
not straightforward, since each country follows its own 
medical, sanitary and legislatory rules. Commonly, the 
use of tDCS devices in research requires an approval 
by the local ethics committee, which, in several 
countries follows, at least partially, the World Medical 
Association-Declaration of Helsinki[135].
For clinical purposes, it is necessary the regulation 
of a new treatment according to the country’s internal 
policies, which is based on ethical aspects, safety and 
clinical evidence of effectiveness. To our knowledge, 
there is no country that regulated the use of tDCS in 
clinical practice as an on-label treatment, although 
the evidence of the benefit of tDCS is increasing. For 
instance, a recent meta-analysis found that active 
tDCS was statistically superior to sham for treatment 
of acute depression[8]. The regulation in several 
countries tends to be very restrictive, since it is also 
used to determinate medical insurance coverage and 
public health politics. Moreover, in our opinion, tDCS 
device should be regulated as a medical device, since 
it fulfills the criteria for this, at least for the United 
States Foods and Drugs Administration[136].
Frequently, the regulation for clinical use also 
defines the professional category that could perform 
the therapy. We advocate that tDCS should have 
similar regulation of the psychotropic medications, 
since it has direct effect in the brain. In our opinion, 
the stimulation could be applied by trained technicians, 
but always with medical indication and supervision, 
although this is not necessarily a consensus in scientific 
community.
Although it is still necessary a better understanding 
of the parameters of stimulation and the long terms 
effect of tDCS for therapy, it is being already used 
in some countries as off-label and compassioned 
treatment. The use in this situation is normally justified 
by the lack of conventional treatment for neurologic 
and psychiatric diseases.
ETHICAL ISSUES
As all medical interventions in clinical practice and 
research, tDCS raises general and specific ethical 
issues that must be promptly addressed. Wider 
ethical issues regarding tDCS encompass the pillars of 
bioethics, namely, the principles of non-maleficence, 
beneficence, autonomy and justice[137]. Nonetheless, 
the definition and overall discussion of these paradigms 
surpass the scope of this section of the paper.
The specific ethical issues raised by the growing 
use of neuromodulation techniques, of which tDCS is a 
part, are plentiful. Topics particularly relevant are: the 
“cosmetic use” of tDCS as a cognitive-enhancement 
procedure (i.e., for non-research or non-therapeutic 
objectives), the hypothetical long-term effects of tDCS 
on other mental faculties of its recipients, and the 
inappropriate assemblage and use of tDCS devices by 
nonmedical population, in nonclinical settings[7,138,139].
There are several medical interventions (both 
pharmacological and non-pharmacological) aimed at 
improving cognitive faculties in some neuropsychiatric 
disorders. For instance, methylphenidate is medically 
approved to treat ADHD, and thereby improve the 
patient’s ability to concentrate and appropriately conclude 
tasks. On the other hand, this drug is knowingly misused 
by healthy populations, who end up taking it to 
improve their performance in situations like academic 
presentations and exams. The same phenomenon 
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could occur with tDCS. Consequentially, an intervention 
initially devised to treat pathological conditions, such 
as major depressive disorder, and lead to recovery of 
secondary cognitive deficits, might mistakenly be used 
for cosmetic cognitive enhancement[138].
The major concern about the indiscriminate use of 
tDCS, especially for cosmetic purposes, is that since 
it is a relatively novel method, and in many ways still 
in phases of research, its long-term side effects are 
not completely known. Despite its notorious short-
term safety with minimal and benign side effects, 
there is preliminary evidence pointing to possible and 
unforeseen interference of tDCS with the individual’s 
social cognition[139], moral judgment[140] and even the 
capacity to tell the truth or deceive others[141]. While 
such effects might be of minimal clinical relevance 
when tDCS is applied correctly in clinical settings, with 
adequate monitoring of individual responses, the same 
cannot be said about its cosmetic use.
Finally, it is important to recognize that while the 
equipment necessary to perform other neuromodulatory 
techniques is expensive and not portable (rTMS, for 
instance), naturally limiting their use in nonclinical 
settings, the device used in tDCS is lightweight, portable 
and can be assembled inexpensively[138]. Moreover, it 
can be used at home, and in fact, there are websites 
and open discussion groups aimed at instructing 
nonmedical population on how to independently apply 
tDCS on oneself.
Therefore, as the practice of tDCS becomes wide-
spread, physicians and researchers need to be very 
attentive to its correct clinical use, its long-term effects 
on cognition, moral judgment and personality, and 
cooperate with governmental regulation regarding 
the manufacture and commercialization of its devices 
and apparel. Needless to mention, all to safeguard the 
appropriate autonomy of our patients, while helping 
them make the best decisions with regard to their 
mental and physical health. 
CONCLUSION 
We hereby presented an overview of tDCS use in 
psychiatry, from its history, through the mechanism of 
action, results in different fields of psychiatry, ethical 
considerations and methodological aspects were 
presented. The main point of emphasis, perhaps, for 
this conclusion is tDCS clinical research - particularly 
randomized controlled-trials, began to be researched 
in psychiatry only recently. Even being a technique 
that has a recent scientific and clinical interest, it has 
already demonstrated that it might be a promising tool 
in the therapeutic arsenal of psychiatric disorders. 
The interest, both academic as of the lay public and 
the media around the tDCS has increased considerably 
in recent years[142]. This interest will probably continue to 
increase, given the promising results that the technique 
has presented in psychiatry and also in other field, such 
as neurology[143]. Along with promising results, comes 
the excitement and interest of the media. The ethical 
aspects surrounding the tDCS is being intensively 
discussed. This is necessary to maintain scientific 
rigor in terms of the information that reaches the lay 
public[142].
With the promising results found in different psychiatric 
disorders, further studies, with robust methodologies, 
should strive to replicate, expand and optimize the 
findings, perhaps testing larger, different samples 
and also varying tDCS parameters such as electrode 
size, dosage, reference electrode, length of sessions, 
number of days of application are still warranted in 
order to provide a definite picture regarding tDCS 
clinical efficacy in psychiatry.
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